logo
Twitter
Discord
Email
logo
Theravance Biopharma, Inc.

Theravance Biopharma, Inc.

NASDAQ•TBPH
CEO: Mr. Rick E. Winningham M.B.A.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2014-05-16
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has licensing and collaboration agreements with Pfizer Inc. for its preclinical skin-selective pan-JAK inhibitor program, as well as Viatris Inc. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
Contact Information
901 Gateway Boulevard, South San Francisco, CA, 94080, United States
650-808-6000
www.theravance.com
Market Cap
$948.10M
P/E (TTM)
57.9
40.4
Dividend Yield
--
52W High
$20.33
52W Low
$7.90
52W Range
87%
Rank60Top 78.6%
2.5
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 2.5 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024

Financial Dashboard

Q3 2025 Data

Revenue

$19.99M+18.51%
4-Quarter Trend

EPS

$0.07-126.92%
4-Quarter Trend

FCF

-$6.51M+24.89%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Nine Month Net Income Surge Net income reached $44.9M for nine months, driven by $75.1M gain from TRELEGY royalty sale.
Total Revenue Increased 35% Total revenues hit $61.6M for nine months, boosted by $7.5M China regulatory milestone payment.
Strong Operating Cash Flow Net cash provided by operating activities was $244.6M, including $225.0M cash from GSK royalty sale.
YUPELRI China Approval Milestone Received $7.5M licensing revenue following YUPELRI regulatory approval by China NMPA in June 2025.

Risk Factors

Ampreloxetine Pipeline Uncertainty Phase 3 CYPRESS study last patient enrolled; top-line data expected in Q1 2026 for nOH indication.
Reliance on Viatris Partnership US commercial success relies on Viatris co-promotion efforts; failure impacts revenue and financial results.
Generic Competition Threat Litigation ongoing with Mankind Pharma regarding YUPELRI generics; settlements reached with most other filers.
Key Personnel Retention Risk Intense competition for skilled personnel in Northern California risks impairing development and commercialization efforts.

Outlook

Ampreloxetine Phase 3 Progress Expect top-line data availability for CYPRESS Phase 3 study in symptomatic nOH patients in Q1 2026.
Strategic Review Committee Active Board committee assessing strategic alternatives to unlock shareholder value; focus remains on disciplined capital allocation.
Liquidity Sufficient Twelve Months Expect current cash, cash equivalents, and marketable securities of $332.7M to fund operations for next twelve months.
Future Financing Needs Possible Future capital needs depend on YUPELRI support and ampreloxetine program expenditures; financing may require equity dilution.

Peer Comparison

Revenue (TTM)

Arvinas, Inc.ARVN
$312.30M
+93.9%
Monte Rosa Therapeutics, Inc.GLUE
$181.54M
+665.1%
Nurix Therapeutics, Inc.NRIX
$83.69M
+48.3%

Gross Margin (Latest Quarter)

Monte Rosa Therapeutics, Inc.GLUE
83.6%
-16.4pp
Nurix Therapeutics, Inc.NRIX
36.7%
+377.4pp
Terns Pharmaceuticals, Inc.TERN
0.0%
+0.0pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
TERN$3.74B-41.4-27.4%0.4%
OLMA$1.76B-14.7-41.5%0.4%
KOD$1.52B-9.8-176.6%28.5%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
2.2%
Moderate Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
50%
Cash Flow Needs Attention

Research & Insights

Next earnings:Feb 25, 2026
|
EPS:$0.44
|
Revenue:-
Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 12, 2025|
    Revenue: $19.99M+18.5%
    |
    EPS: $0.07-126.9%
    Beat

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 13, 2025|
    Revenue: $26.20M+83.7%
    |
    EPS: $1.09-420.6%
    Beat

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 12, 2025|
    Revenue: $15.39M+6.1%
    |
    EPS: $-0.27+12.5%
    Miss

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Mar 7, 2025|
    Revenue: $64.38M+12.1%
    |
    EPS: $-1.15-15.0%
    Miss

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 14, 2024|
    Revenue: $16.87M+7.5%
    |
    EPS: $-0.26+52.9%
    Miss

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 8, 2024|
    Revenue: $14.26M+3.7%
    |
    EPS: $-0.34+21.4%
    Miss

  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 15, 2024|
    Revenue: $14.50M+39.2%
    |
    EPS: $-0.24-31.4%
    Beat

  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Mar 1, 2024|
    Revenue: $57.42M+11.8%
    |
    EPS: $-1.00+20.6%
    Miss